Ron Brookmeyer1, Nada Abdalla2. 1. Department of Biostatistics, University of California, Los Angeles, CA, USA. Electronic address: rbrookmeyer@ucla.edu. 2. Department of Biostatistics, University of California, Los Angeles, CA, USA.
Abstract
INTRODUCTION: Lifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten-year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease. METHODS: We used a multistate model for the disease process together with US death rates. RESULTS: Lifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90-year old and 29.3% for a 65-year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%. DISCUSSION: Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.
INTRODUCTION: Lifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten-year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease. METHODS: We used a multistate model for the disease process together with US death rates. RESULTS: Lifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90-year old and 29.3% for a 65-year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%. DISCUSSION: Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.
Authors: Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe Journal: Ann Neurol Date: 2011-01 Impact factor: 10.422
Authors: I Contador; F Bermejo-Pareja; A J Mitchell; R Trincado; A Villarejo; Á Sánchez-Ferro; J Benito-León Journal: Eur J Neurol Date: 2013-10-15 Impact factor: 6.089
Authors: Stephanie J B Vos; Frans Verhey; Lutz Frölich; Johannes Kornhuber; Jens Wiltfang; Wolfgang Maier; Oliver Peters; Eckart Rüther; Flavio Nobili; Silvia Morbelli; Giovanni B Frisoni; Alexander Drzezga; Mira Didic; Bart N M van Berckel; Andrew Simmons; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Muscio; Sanna-Kaisa Herukka; Eric Salmon; Christine Bastin; Anders Wallin; Arto Nordlund; Alexandre de Mendonça; Dina Silva; Isabel Santana; Raquel Lemos; Sebastiaan Engelborghs; Stefan Van der Mussele; Yvonne Freund-Levi; Åsa K Wallin; Harald Hampel; Wiesje van der Flier; Philip Scheltens; Pieter Jelle Visser Journal: Brain Date: 2015-02-17 Impact factor: 13.501
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182
Authors: Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-06-01 Impact factor: 21.566
Authors: Medellena Maria Glymour; Adam Mark Brickman; Mika Kivimaki; Elizabeth Rose Mayeda; Geneviève Chêne; Carole Dufouil; Jennifer Jaie Manly Journal: Eur J Epidemiol Date: 2018-06-09 Impact factor: 8.082
Authors: Emily A Largent; Maramawit Abera; Kristin Harkins; Sara J Feldman; Wendy R Uhlmann; J Scott Roberts; Jason Karlawish Journal: J Am Geriatr Soc Date: 2021-07-12 Impact factor: 5.562
Authors: Carolyn M Rutter; Ifeanyi Edochie; Esther M Friedman; Mary E Slaughter; Margaret M Weden Journal: Med Decis Making Date: 2021-06-14 Impact factor: 2.583
Authors: Peter J Snyder; Jessica Alber; Clemens Alt; Lisa J Bain; Brett E Bouma; Femke H Bouwman; Delia Cabrera DeBuc; Melanie C W Campbell; Maria C Carrillo; Emily Y Chew; M Francesca Cordeiro; Michael R Dueñas; Brian M Fernández; Maya Koronyo-Hamaoui; Chiara La Morgia; Roxana O' Carare; Srinivas R Sadda; Peter van Wijngaarden; Heather M Snyder Journal: Alzheimers Dement Date: 2020-10-08 Impact factor: 21.566